Last reviewed · How we verify
BKM120 and Erlotinib
BKM120 is a PI3K inhibitor, and Erlotinib is a tyrosine kinase inhibitor targeting EGFR.
BKM120 is a PI3K inhibitor, and Erlotinib is a tyrosine kinase inhibitor targeting EGFR. Used for Non-small cell lung cancer, Pancreatic cancer.
At a glance
| Generic name | BKM120 and Erlotinib |
|---|---|
| Also known as | Buparlisib (BKM 120) and Tarceva (erlotinib) |
| Sponsor | SCRI Development Innovations, LLC |
| Drug class | PI3K inhibitor, EGFR tyrosine kinase inhibitor |
| Target | PI3K, EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BKM120 works by inhibiting the PI3K/AKT signaling pathway, which is involved in cell proliferation and survival. Erlotinib, on the other hand, targets the epidermal growth factor receptor (EGFR), a protein that promotes cell division and growth. By inhibiting these pathways, BKM120 and Erlotinib aim to slow down or stop the growth of cancer cells.
Approved indications
- Non-small cell lung cancer
- Pancreatic cancer
Common side effects
- Diarrhea
- Rash
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR (PHASE1)
- Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BKM120 and Erlotinib CI brief — competitive landscape report
- BKM120 and Erlotinib updates RSS · CI watch RSS
- SCRI Development Innovations, LLC portfolio CI